Stocktoria

Lyell Immunopharma, Inc. LYEL

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-17
Chart by TradingView
1/9
Piotroski F — financial health
-13.93
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$36,000$61,000$130,000$84.7M$10.7M
Operating income-$269.4M-$358.8M-$247.0M-$187.1M-$214.8M
Net income-$274.4M-$343.0M-$234.6M-$183.1M-$250.2M
Operating cash flow-$150.0M-$162.4M-$163.7M-$169.6M-$126.2M
Free cash flow-$150.8M-$162.9M-$166.4M-$193.8M-$191.8M
Total assets$340.1M$490.9M$750.0M$937.6M$1.1B
Total liabilities$91.8M$108.0M$95.1M$104.3M$197.6M
Shareholders' equity$248.2M$382.8M$655.0M$833.3M$929.8M
Ratios
Operating margin-748344.4%-588123.0%-190006.2%-220.9%-2016.7%
Net margin-762355.6%-562285.2%-180486.2%-216.2%-2349.5%
FCF margin-418900.0%-266980.3%-127984.6%-228.9%-1800.5%
Return on assets-80.7%-69.9%-31.3%-19.5%-22.2%
Return on equity-110.6%-89.6%-35.8%-22.0%-26.9%
Current ratio5.287.0616.0717.5913.40
Revenue growth-41.0%-53.1%-99.8%695.1%37.3%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC116,411$2.3M
Point72 Asset Management, L.P.21,292$427,118

Why these scores methodology →

Piotroski F-score: 1/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -13.93 (distress)

  • Working capital / assets 0.622
  • Retained earnings / assets -4.763
  • EBIT / assets -0.792
  • Equity / liabilities 2.702

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001806952 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.